Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 5
Submit an article Journal homepage
343
Views
11
CrossRef citations to date
0
Altmetric
Clinical Trial Report

The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure

Sanjay Dandamudi Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
&
Horng H Chen Department of Internal Medicine, Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA. [email protected]; Department of Internal Medicine, Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA. [email protected]
Pages 557-563 | Published online: 10 Jan 2014

References

  • Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation 123(4), e18–e209 (2011).
  • Hummel SL, Pauli NP, Krumholz HM et al. Thirty-day outcomes in Medicare patients with heart failure at heart transplant centers. Circ. Heart Fail. 3(2), 244–252 (2010).
  • Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am. J. Cardiol. 101(7), 1016–1022 (2008).
  • Nieminen MS, Böhm M, Cowie MR et al.; ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26(4), 384–416 (2005).
  • Marcus LS, Hart D, Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94(12), 3184–3189 (1996).
  • Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail. 4(1), 37–44 (1998).
  • Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 343(4), 246–253 (2000
  • Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for the treatment of decompensated congestive heart failure: a randomized controlled trial, JAMA 287, 1531–1540 (2002).
  • Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12), 1487–1491 (2005).
  • Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293(15), 1900–1905 (2005).
  • O’Connor CM, Starling RC, Hernandez AF et al. Clinical protocol: Double-blind, placebo-controlled, multicenter acute study of clinical effectiveness of nesiritide in subjects with decompensated heart failure. N. Engl. J. Med. 365, 32–43 (2011).
  • Hernandez AF, O’Connor CM, Starling RC et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am. Heart J. 157(2), 271–277 (2009).
  • O’Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32–43 (2011).
  • Riter HG, Redfield MM, Burnett JC, Chen HH. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J. Am. Coll. Cardiol. 47(11), 2334–2335 (2006).
  • Noviasky JA, Kelberman M, Whalen KM, Guharoy R, Darko W. Science or fiction: use of nesiritide as a first-line agent? Pharmacotherapy 23(8), 1081–1083 (2003).
  • de Lissovoy G, Stier DM, Ciesla G, Munger M, Burger AJ. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am. J. Cardiol. 92(5), 631–633 (2003).
  • Abraham WT, Adams KF, Fonarow GC et al.; ADHERE Scientific Advisory Committee and Investigators ADHERE Study Group; In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol. 46(1), 57–64 (2005).
  • Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshani M. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J. Cardiovasc. Pharmacol. Ther. 9(4), 227–241 (2004).
  • Chen HH, Burnett JC Jr. Clinical application of the natriuretic peptides in heart failure. Eur. Heart J. Suppl. 
8(Suppl. E), e18–e25 (2006).
  • Chen HH, Cataliotti A, Schirger JA, Martin FL, Harstad LK, Burnett JC Jr. Local renal delivery of a natriuretic peptide. J. Am. Coll. Cardiol. 53, 735–1097 (2009).
  • Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 105(8), 999–1003 (2002).
  • Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC Jr. Maximizing the renal cyclic 3´-5´-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J. Am. Soc. Nephrol. 17(10), 2742–2747 (2006).
  • Lüss H, Mitrovic V, Seferovic PM et al. Renal effects of ularitide in patients with decompensated heart failure. Am. Heart J. 155(6), 1012.e1–1012.e8 (2008).
  • Nomura F, Kurobe N, Mori Y et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ. J. 72(11), 1777–1786 (2008).
  • Sezai A, Hata M, Niino T et al. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J. Am. Coll. Cardiol. 55(17), 1844–1851 (2010).
  • Sezai A, Hata M, Niino T et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J. Am. Coll. Cardiol. 58(9), 897–903 (2011).
  • Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J. Am. Coll. Cardiol. 52(1), 60–68 (2008).
  • Lee CY, Chen HH, Lisy O et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J. Clin. Pharmacol. 49(6), 668–673 (2009).
  • Cataliotti A, Schirger JA, Martin FL et al. Oral human brain natriuretic peptide activates cyclic guanosine 3´,5´-monophosphate and decreases mean arterial pressure. Circulation 112(6), 836–840 (2005).
  • Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett JC Jr. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J. Card. Fail. 10(2), 115–119 (2004).
  • Chen HH, Glockner J, Schirger JA et al. Novel protein therapeutics for chronic systolic heart failure: chronic subcutaneous BNP administration (NICE BNP). J. Cardiac Fail. 16(11), 912–913 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.